The $400 million the United States congress removed from a list of funding programmes the Trump administration wants to cut doesn’t cancel the cuts to HIV and TB programmes made in February ...

Chicago-area groups that support LGBTQ+ individuals are navigating an uncertain landscape while bracing for federal funding ...

Why a twice‑yearly injection might prove to be a good shot Lenacapavir is a first-in-class HIV drug that works by targeting ...

Although Uganda participated in a groundbreaking trial for Lenacapavir—an injectable drug proven effective in preventing ...

President Donald Trump is removing a large portion of HIV funding he previously greenlit for a future without AIDs. For ...

Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...

President Donald Trump is removing a large portion of HIV funding he previously greenlit for a future without AIDs. For ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

WHO recommends twice-yearly injectable lenacapavir for HIV prevention, expanding PrEP options for key populations.

A new kind of HIV prevention is making it easier for those at risk to stay protected, thanks to a twice-yearly injection now ...